LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 5 of total 5

Search options

  1. Article: Heart Transplantation From Hepatitis C-Positive Donors in the Era of Direct Acting Antiviral Therapy: A Comprehensive Literature Review.

    Bruno, Schnegg / Nicole, Bart / Nila J, Dharan / Gail, Matthews / James, Nadel / Peter S, Macdonald / Christopher S, Hayward

    Transplantation direct

    2019  Volume 5, Issue 9, Page(s) e486

    Abstract: While heart transplantation is a highly effective treatment in patients with advanced heart failure, the number of people waiting for a transplant exceeds the number of available donors. With the advent of direct acting antivirals (DAA) for the ... ...

    Abstract While heart transplantation is a highly effective treatment in patients with advanced heart failure, the number of people waiting for a transplant exceeds the number of available donors. With the advent of direct acting antivirals (DAA) for the eradication of Hepatitis C, the heart transplant donor pool has been expanded to include donors with untreated Hepatitis C. To help with the development of future protocols for Hepatitis C-positive heart transplants, we performed a review of the literature on DAA therapy in the context of heart transplantation.
    Methods: We searched MEDLINE, EMBASE, OVIDE JOURNAL, and GOOGLE SCHOLAR for papers published between 01.01.2011 and 01.06.2019 using key words "heart transplantation" associated with "hepatitis C."
    Results: After removing duplicates, we screened 78 articles and retained 16 for primary analysis and 20 for sustained virologic response 12 weeks after completion of the DAA therapy (SVR-12). The data from 62 patients were extracted from these publications. Fifty-six (90%) patients had donor-derived hepatitis C and 6 (10%) patients were chronically infected with hepatitis C before transplantation. All living transplanted patients achieved SVR-12, defined as hepatitis C virus RNA below the limit of detection 12 weeks after treatment completion. Treatment duration ranged from 4 to 24 weeks. Clinically relevant modification to the dosing of immunosuppressive mediations during DAA therapy was documented in only 1 patient (1.6%). Six (14%) patients experienced rejection during DAA therapy.
    Conclusions: Despite different timings of initiation of DAA therapy across the included studies, there were no differences in sustained viral clearance. Early commencement of DAA with a potentially shorter treatment duration (<8 wk) is appealing; however, further studies are required before recommending this approach.
    Language English
    Publishing date 2019-08-23
    Publishing country United States
    Document type Journal Article
    ISSN 2373-8731
    ISSN 2373-8731
    DOI 10.1097/TXD.0000000000000928
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Emergence and antibody evasion of BQ, BA.2.75 and SARS-CoV-2 recombinant sub-lineages in the face of maturing antibody breadth at the population levelResearch in context

    Anouschka Akerman / Vanessa Milogiannakis / Tyra Jean / Camille Esneau / Mariana Ruiz Silva / Timothy Ison / Christina Fichter / Joseph A. Lopez / Deborah Chandra / Zin Naing / Joanna Caguicla / Daiyang Li / Gregory Walker / Supavadee Amatayakul-Chantler / Nathan Roth / Sandro Manni / Thomas Hauser / Thomas Barnes / Anna Condylios /
    Malinna Yeang / Maureen Wong / Charles S.P. Foster / Kenta Sato / Sharon Lee / Yang Song / Lijun Mao / Allison Sigmund / Amy Phu / Ann Marie Vande More / Stephanie Hunt / Mark Douglas / Ian Caterson / Warwick Britton / Kerrie Sandgren / Rowena Bull / Andrew Lloyd / Jamie Triccas / Stuart Tangye / Nathan W. Bartlett / David Darley / Gail Matthews / Damien J. Stark / Kathy Petoumenos / William D. Rawlinson / Ben Murrell / Fabienne Brilot / Anthony L. Cunningham / Anthony D. Kelleher / Anupriya Aggarwal / Stuart G. Turville

    EBioMedicine, Vol 90, Iss , Pp 104545- (2023)

    2023  

    Abstract: Summary: Background: The Omicron era of the COVID-19 pandemic commenced at the beginning of 2022 and whilst it started with primarily BA.1, it was latter dominated by BA.2 and the related sub-lineage BA.5. Following resolution of the global BA.5 wave, a ... ...

    Abstract Summary: Background: The Omicron era of the COVID-19 pandemic commenced at the beginning of 2022 and whilst it started with primarily BA.1, it was latter dominated by BA.2 and the related sub-lineage BA.5. Following resolution of the global BA.5 wave, a diverse grouping of Omicron sub-lineages emerged derived from BA.2, BA.5 and recombinants thereof. Whilst emerging from distinct lineages, all shared similar changes in the Spike glycoprotein affording them an outgrowth advantage through evasion of neutralising antibodies. Methods: Over the course of 2022, we monitored the potency and breadth of antibody neutralization responses to many emerging variants in the Australian community at three levels: (i) we tracked over 420,000 U.S. plasma donors over time through various vaccine booster roll outs and Omicron waves using sequentially collected IgG pools; (ii) we mapped the antibody response in individuals using blood from stringently curated vaccine and convalescent cohorts. (iii) finally we determine the in vitro efficacy of clinically approved therapies Evusheld and Sotrovimab. Findings: In pooled IgG samples, we observed the maturation of neutralization breadth to Omicron variants over time through continuing vaccine and infection waves. Importantly, in many cases, we observed increased antibody breadth to variants that were yet to be in circulation. Determination of viral neutralization at the cohort level supported equivalent coverage across prior and emerging variants with isolates BQ.1.1, XBB.1, BR.2.1 and XBF the most evasive. Further, these emerging variants were resistant to Evusheld, whilst increasing neutralization resistance to Sotrovimab was restricted to BQ.1.1 and XBF. We conclude at this current point in time that dominant variants can evade antibodies at levels equivalent to their most evasive lineage counterparts but sustain an entry phenotype that continues to promote an additional outgrowth advantage. In Australia, BR.2.1 and XBF share this phenotype and, in contrast to global variants, are ...
    Keywords SARS-CoV-2 ; Variants ; TMPRSS2 ; Covid-19 ; Neutralising antibodies ; Sotrovimab ; Medicine ; R ; Medicine (General) ; R5-920
    Language English
    Publishing date 2023-04-01T00:00:00Z
    Publisher Elsevier
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  3. Article ; Online: Invasive Amebiasis in Men Who Have Sex with Men, Australia

    Damien Stark / Sebastian J. van Hal / Gail Matthews / John Harkness / Deborah Marriott

    Emerging Infectious Diseases, Vol 14, Iss 7, Pp 1141-

    2008  Volume 1143

    Abstract: Entamoeba histolytica is a pathogenic ameba that has recently been recognized as an emerging pathogen in men who have sex with men (MSM) in Asia-Pacific countries where it is not endemic, i.e., Japan, Taiwan, and Republic of Korea. We report locally ... ...

    Abstract Entamoeba histolytica is a pathogenic ameba that has recently been recognized as an emerging pathogen in men who have sex with men (MSM) in Asia-Pacific countries where it is not endemic, i.e., Japan, Taiwan, and Republic of Korea. We report locally acquired invasive amebiasis in Sydney, Australia, exclusively in MSM.
    Keywords Entamoeba histolytica ; amebiasis ; men who have sex with men ; dispatch ; Australia ; Medicine ; R ; Infectious and parasitic diseases ; RC109-216
    Language English
    Publishing date 2008-07-01T00:00:00Z
    Publisher Centers for Disease Control and Prevention
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  4. Article ; Online: A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2

    Thomas S. Fulford / Huy Van / Nicholas A. Gherardin / Shuning Zheng / Marcin Ciula / Heidi E. Drummer / Samuel Redmond / Hyon-Xhi Tan / Irene Boo / Rob J. Center / Fan Li / Samantha L. Grimley / Bruce D. Wines / Thi H.O. Nguyen / Francesca L. Mordant / Paula Ellenberg / Louise C. Rowntree / Lukasz Kedzierski / Allen C. Cheng /
    Denise L. Doolan / Gail Matthews / Katherine Bond / P. Mark Hogarth / Zoe McQuilten / Kanta Subbarao / Katherine Kedzierska / Jennifer A. Juno / Adam K. Wheatley / Stephen J. Kent / Deborah A. Williamson / Damian F.J. Purcell / David A. Anderson / Dale I. Godfrey

    EBioMedicine, Vol 74, Iss , Pp 103729- (2021)

    2021  

    Abstract: Background: As vaccines against SARS-CoV-2 are now being rolled out, a better understanding of immunity to the virus, whether from infection, or passive or active immunisation, and the durability of this protection is required. This will benefit from the ...

    Abstract Background: As vaccines against SARS-CoV-2 are now being rolled out, a better understanding of immunity to the virus, whether from infection, or passive or active immunisation, and the durability of this protection is required. This will benefit from the ability to measure antibody-based protection to SARS-CoV-2, ideally with rapid turnaround and without the need for laboratory-based testing. Methods: We have developed a lateral flow POC test that can measure levels of RBD-ACE2 neutralising antibody (NAb) from whole blood, with a result that can be determined by eye or quantitatively on a small instrument. We compared our lateral flow test with the gold-standard microneutralisation assay, using samples from convalescent and vaccinated donors, as well as immunised macaques. Findings: We show a high correlation between our lateral flow test with conventional neutralisation and that this test is applicable with animal samples. We also show that this assay is readily adaptable to test for protection to newly emerging SARS-CoV-2 variants, including the beta variant which revealed a marked reduction in NAb activity. Lastly, using a cohort of vaccinated humans, we demonstrate that our whole-blood test correlates closely with microneutralisation assay data (specificity 100% and sensitivity 96% at a microneutralisation cutoff of 1:40) and that fingerprick whole blood samples are sufficient for this test. Interpretation: Taken together, the COVID-19 NAb-testTM device described here provides a rapid readout of NAb based protection to SARS-CoV-2 at the point of care. Funding: Support was received from the Victorian Operational Infrastructure Support Program and the Australian Government Department of Health. This work was supported by grants from the Department of Health and Human Services of the Victorian State Government; the ARC (CE140100011, CE140100036), the NHMRC (1113293, 2002317 and 1116530), and Medical Research Future Fund Awards (2005544, 2002073, 2002132). Individual researchers were supported by an NHMRC ...
    Keywords SARS-CoV-2 ; Neturalising antibodies ; Lateral flow assay ; Point of care test ; Medicine ; R ; Medicine (General) ; R5-920
    Subject code 650
    Language English
    Publishing date 2021-12-01T00:00:00Z
    Publisher Elsevier
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  5. Article ; Online: IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort

    Vijayaprakash Suppiah / Silvana Gaudieri / Nicola J Armstrong / Kate S O'Connor / Thomas Berg / Martin Weltman / Maria Lorena Abate / Ulrich Spengler / Margaret Bassendine / Gregory J Dore / William L Irving / Elizabeth Powell / Margaret Hellard / Stephen Riordan / Gail Matthews / David Sheridan / Jacob Nattermann / Antonina Smedile / Tobias Müller /
    Emma Hammond / David Dunn / Francesco Negro / Pierre-Yves Bochud / Simon Mallal / Golo Ahlenstiel / Graeme J Stewart / Jacob George / David R Booth / International Hepatitis C Genetics Consortium (IHCGC)

    PLoS Medicine, Vol 8, Iss 9, p e

    a cross-sectional study.

    2011  Volume 1001092

    Abstract: Background To date, drug response genes have not proved as useful in clinical practice as was anticipated at the start of the genomic era. An exception is in the treatment of chronic hepatitis C virus (HCV) genotype 1 infection with pegylated interferon- ... ...

    Abstract Background To date, drug response genes have not proved as useful in clinical practice as was anticipated at the start of the genomic era. An exception is in the treatment of chronic hepatitis C virus (HCV) genotype 1 infection with pegylated interferon-alpha and ribavirin (PegIFN/R). Viral clearance is achieved in 40%-50% of patients. Interleukin 28B (IL28B) genotype predicts treatment-induced and spontaneous clearance. To improve the predictive value of this genotype, we studied the combined effect of variants of IL28B with human leukocyte antigen C (HLA-C), and its ligands the killer immunoglobulin-like receptors (KIR), which have previously been implicated in HCV viral control. Methods and findings We genotyped chronic hepatitis C (CHC) genotype 1 patients with PegIFN/R treatment-induced clearance (n = 417) and treatment failure (n = 493), and 234 individuals with spontaneous clearance, for HLA-C C1 versus C2, presence of inhibitory and activating KIR genes, and two IL28B SNPs, rs8099917 and rs12979860. All individuals were Europeans or of European descent. IL28B SNP rs8099917 "G" was associated with absence of treatment-induced clearance (odds ratio [OR] 2.19, p = 1.27×10(-8), 1.67-2.88) and absence of spontaneous clearance (OR 3.83, p = 1.71×10(-14), 2.67-5.48) of HCV, as was rs12979860, with slightly lower ORs. The HLA-C C2C2 genotype was also over-represented in patients who failed treatment (OR 1.52, p = 0.024, 1.05-2.20), but was not associated with spontaneous clearance. Prediction of treatment failure improved from 66% with IL28B to 80% using both genes in this cohort (OR 3.78, p = 8.83×10(-6), 2.03-7.04). There was evidence that KIR2DL3 and KIR2DS2 carriage also altered HCV treatment response in combination with HLA-C and IL28B. Conclusions Genotyping for IL28B, HLA-C, and KIR genes improves prediction of HCV treatment response. These findings support a role for natural killer (NK) cell activation in PegIFN/R treatment-induced clearance, partially mediated by IL28B.
    Keywords Medicine ; R
    Subject code 616
    Language English
    Publishing date 2011-09-01T00:00:00Z
    Publisher Public Library of Science (PLoS)
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

To top